Clinical Trial Update: Istradefylline for Parkinson Disease With Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial of istradefylline for Parkinson disease with cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Parkinson Disease

Drugs mentioned

• Nourianz (istradefylline)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Parkinson Disease, Cognitive Impairment | Phase 2 | Status: COMPLETED